

Review Article

Inducible Clindamycin-Resistant *Staphylococcus aureus* Strains in Africa: A Systematic Review

Muluneh Assefa 

Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia

Correspondence should be addressed to Muluneh Assefa; mulunehassefa2010@gmail.com

Received 2 February 2022; Accepted 7 April 2022; Published 19 April 2022

Academic Editor: Faham Khamesipour

Copyright © 2022 Muluneh Assefa. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Excessive use of clindamycin enhances the acquisition of inducible clindamycin-resistant *S. aureus* strains, which is a significant health problem in Africa. The main objective of this review study was to determine the prevalence of inducible clindamycin resistance and related genes among *S. aureus* isolates in Africa. **Methods.** A qualitative systematic review was conducted on inducible clindamycin resistance among *S. aureus* isolates in Africa using electronic databases such as Google Scholar and PubMed. Articles published in English before 2021 were selected, and relevant data were extracted, collected, and analyzed. **Results.** In our search, 22 articles met the eligibility criteria for this review study. Of 3064 total *S. aureus* isolates, 605 had iMLSb phenotype. The overall prevalence of inducible clindamycin resistance in *S. aureus* isolates was 19.8% with a range of 2.9% to 44.0%. A high number of iMLSb phenotypes were observed in MRSA isolates (3.6–77.8%) than MSSA (0–58.8%). The overall prevalence of the iMLSb phenotype in MRSA strains was 26.8% (279/1041). The maximum peak prevalence of inducible clindamycin resistance among *S. aureus* isolates recorded in the continent was 44.0% in Egypt, followed by 35.8% in Libya and 33.3% in Uganda in 2017, 2007, and 2013, respectively. The highest prevalence of iMLSb phenotype in MRSA strains was reported in Egypt, 77.8%, followed by Nigeria, 75.0%, and Libya, 66.2%. Among the recovered drug-resistance genes, *ermA*, *ermC*, and *msrA* genes were commonly detected in Egypt with 67.9%, 70.0%, and 70.0% prevalence, respectively. **Conclusion.** This review highlights a higher inducible resistance of *S. aureus*, including MRSA strains to clindamycin in the continent. Regular screening of these strains, wise use of clindamycin, and molecular detection and genotyping of resistant genes are urgent.

1. Introduction

Staphylococcus aureus is normally found in human skin and mucous membranes. It is a common human pathogen that causes skin and soft-tissue infections, abscesses, pneumonia, osteomyelitis, endocarditis, arthritis, and sepsis in both the community and hospital environment, and the spread of methicillin-resistant *Staphylococcus aureus* (MRSA) through the acquisition of highly transmissible *mecA/mecC* genes has made treatment difficult [1, 2].

Even though the global average incidence of MRSA is 40.0%, reports from African countries reveal rates ranging from 12.0 to 80.0%, with some countries exceeding 82.0% [3, 4]. Antimicrobial resistance has become a severe health hazard worldwide, and its burden has increased in Africa

because of a highly infectious disease burden, poor hygiene, lack of environmental sanitation, and poor infection control. The treatment of MRSA infections in African nations is problematic due to the lack of antibiotics with proven efficacy [5]. The rising prevalence of community-acquired MRSA has sparked interest in using macrolide-lincosamide-streptogramin (MLSb) antibiotics, particularly clindamycin to treat *S. aureus*-associated pneumonia and skin and soft-tissue infections [6].

Clindamycin is the chosen antibiotic because of its superior pharmacokinetics, availability in intravenous and oral formulations with 90% oral bioavailability, low cost, strong tissue penetration, accumulation in deep abscesses, and capacity to inhibit toxin generation in *S. aureus* [7]. Excessive use of clindamycin, on the other hand, enhanced the

acquisition of inducible resistance, leading to therapeutic failure [8]. The main mechanisms of resistance in the MLSB drugs include target site alteration, efflux pump expression, and mutation [9]. The MLSB phenotype can be either constitutive (cMLSB phenotype) in which rRNA methylase is always produced) or inducible (iMLSB phenotype) in which methylase is produced only when an inducing substance like erythromycin is present. During treatment, iMLSB phenotypes can be mutated into cMLSB phenotypes [10]. Owing to this, the Clinical and Laboratory Standards Institute (CLSI) recommends using the double-disk diffusion method (*D*-test) for detecting inducible resistance to clindamycin among *Staphylococcus aureus* isolates [11].

In Africa, *S. aureus* is becoming increasingly resistant to clindamycin due to clinicians' rash use of antibiotics without performing *D*-test and lack of laboratory facilities for molecular approaches such as polymerase chain reaction (PCR) based resistance gene detection. Although there has been published research on inducible clindamycin resistance, little is known about its dissemination and clinical significance in Africa, necessitating a compilation of data from the continent. To fill this gap, this systematic review provides an updated summary and valuable data. Therefore, this study mainly aimed to determine the prevalence of inducible clindamycin resistance and related resistance genes among *S. aureus* isolates in Africa.

2. Methods

2.1. Literature Search Strategy in Databases. A systematic literature search was performed on published articles for inducible clindamycin resistance among *S. aureus* isolates in Africa with a study period before 2021 using electronic databases such as PubMed and Google Scholar. The following keywords were used with the help of Boolean operators: "inducible clindamycin resistance" OR "macrolide-lincosamide-streptogramin B resistance" OR "*D*-test" AND ("*Staphylococcus aureus*" OR "*S. aureus*" OR "methicillin-resistant *Staphylococcus aureus*" OR "methicillin-sensitive *Staphylococcus aureus*" OR MRSA OR MSSA) AND (Africa). The references of included articles were appropriately scanned to access related articles of interest. The literature search was not limited to a specific publication or year of study. In this review, we considered all studies that described inducible clindamycin resistance in *S. aureus* obtained from any type of human study participant in Africa. The procedure of eligible study selection is demonstrated in Figure 1.

2.2. Study Selection and Eligibility Criteria. All studies from Africa reported the following information in the full-text selected:

- (I) Articles performed *D*-test for detecting the iMLSB phenotype in *S. aureus* according to CLSI guideline
- (II) All articles published with a study period until 2021




FIGURE 1: Flow diagram showing the procedure of eligible study selection to undergo review.

- (III) Articles published and written in English
- (IV) Articles with well-defined objectives and methodology
- (V) Articles from a human source of specimen
- (VI) Articles including data on the number of *S. aureus* isolates and any source of specimen used
- (VII) Studies which investigated antibiotic resistance genes using PCR were also summarized

Articles that lacked all or most of the above variables, such as abstract only, not in English, duplicate reports, ambiguous results, and articles with overlapping data, were excluded.

2.3. Assessment of the Study Validity. The validity of each study was illustrated by the use of the selection and eligibility criteria described above, thereby excluding studies that have unclear results, are unrepresentative of the human population, or studies with noncomparable data. Studies vary in specimen source, and the human study population was not excluded.

2.4. Data Extraction and Collection. Essential data were extracted from eligible studies using Excel spreadsheet format, and any discrepancies were handled by the author. The following information was extracted from the selected studies: the percentage of iMLSB phenotype detected, the number of *S. aureus* isolates identified, the study period, the study population, geographic area where the study was conducted, the source of the specimen, the method of detection, the coexistence of antibiotic resistance genes, and the references were all considered.

2.5. Data Synthesis and Analysis. The data were synthesized qualitatively. Because of the relatively small number of studies used, inconsistencies between studies, and

heterogeneity of the study populations between countries, we did not perform a quantitative synthesis. Data were summarized in the extraction table and analyzed manually. The overall prevalence of inducible clindamycin resistance in *S. aureus* or MRSA strains was calculated using the following formula:

$$\text{overall prevalence} = \frac{\text{sum of the iMLSB phenotypes}}{\text{total number of } S. \text{ aureus/MRSA}} * 100\%. \quad (1)$$

According to the United Nations list of 54 African countries, the map of Africa was created using the website (<https://mapchart.net/>). Finally, charts were created using the Excel 2019 software.

3. Results

3.1. Literature Search. In electronic database searches, 465 articles were retrieved. After removing duplicates, 361 articles were avoided based on their titles and abstracts. The full-text articles of the remaining 104 articles were reviewed in detail for eligibility. Of these, 82 articles were discarded after the full-text had been reviewed for appropriate methodology, study population, the source of the specimens, clear result, and standard microbiological technique. Finally, 22 articles were included in the synthesis of the review (Figure 1).

3.2. General Characteristics of the Studies Included in This Systematic Review. The main characteristics of the 22 studies from 8 African countries included in this systematic review have been summarized in Table 1. All the studies used *D*-test for detecting inducible clindamycin resistance in *S. aureus* isolates, but some of them also used PCR for confirming the MLSB resistance genes. Studies used various specimens from human sources including swabs such as nasal, vaginal, cervical, urethral, wound, throat, ear, eye, and palm, respiratory specimens such as sputum, bronchoalveolar lavages, and tracheal aspirates, pus, urine, catheter, blood, semen, cerebrospinal fluid, pleural fluid, ascetic fluid, synovial fluid, and others. In this systematic review, most of the studies were conducted in clinical patients admitted to hospitals or outpatients, and the rest were conducted in healthy individuals with *S. aureus* carriers. Out of six studies that performed PCR for detecting MLSB resistance genes, 5 (83.3%) were conducted in Egypt and 1 (16.7%) was in Uganda. The detection rate of inducible clindamycin resistance in MRSA and MSSA was not reported in Ethiopian studies and a study from Uganda. Additionally, the prevalence of the iMLSB phenotype was relatively higher in children and burn patients (Table 1).

4. The Geographic Area of Studies Reported Inducible Clindamycin-Resistant *S. aureus* in Africa

The incidence of inducible clindamycin resistance in *S. aureus* isolates was reported in eight countries (Libya,

Egypt, Tanzania, Ethiopia, Nigeria, Sudan, Uganda, and Côte d'Ivoire) in three geographic regions of Africa such as eastern (9 studies), northern (8 studies), and western (5 studies) regions based on United Nations classification (Figure 2). Most of the studies reporting inducible clindamycin resistance in *S. aureus* were conducted in Egypt (75%, 6/8), followed by Tanzania (50%, 4/8), Ethiopia (50%, 4/8), Nigeria (50%, 4/8), Libya, Sudan, Uganda, and Côte d'Ivoire (12.5%, 1/8) each (Figure 2).

4.1. The Prevalence of Inducible Clindamycin Resistance among *S. aureus* Isolates. In our review, we assessed the overall prevalence of inducible clindamycin resistance among *S. aureus* isolates by adding all iMLSB phenotypes and dividing it by the total number of *S. aureus* isolates. The total number of *S. aureus* isolates in the review was found to be 3064. Among the total *S. aureus* isolates, 605 had an iMLSB phenotype. Thus, the overall prevalence of inducible clindamycin resistance in this review was found to be 19.8%. Similarly, the overall prevalence of the iMLSB phenotype in MRSA was calculated by adding all the number of iMLSB phenotypes and dividing it by the total number of MRSA isolates, which was 26.8% (279/1041). Studies were conducted between 2007 and 2021 from different areas of the country [12–33].

The prevalence of inducible clindamycin resistance among *S. aureus* isolates varies from place to place due to the difference in local clindamycin resistance. Inducible clindamycin resistance was first reported in 2007 in Libya among burn patients [12]. The prevalence range of inducible clindamycin resistance among the *S. aureus* isolates was 2.9–44% [12–33] (Figure 3). The highest peak prevalence of inducible clindamycin resistance among *S. aureus* isolates documented on the continent was 44.0% in 2017 in Egypt [21] and the minimum prevalence was 2.9% from Côte d'Ivoire [24]. In 2007 and 2013, respectively, the second (35.8%) [12] and third (33.3%) [17] highest peaks of inducible clindamycin resistance prevalence were reported. Despite a 33.3% record of inducible clindamycin resistance in 2013, there has been a progressive drop in the prevalence of inducible clindamycin resistance since 2007 [17]. A similar 10.0% prevalence was observed in Egypt during 2017 and 2018 [23, 27]. Generally, there were heterogeneous distribution and prevalence rate of inducible clindamycin resistance among *S. aureus* isolates in Africa according to the reviewed studies (Figure 3).

A high number of iMLSB phenotypes were observed in MRSA isolates, ranging from 3.6 to 77.8% than MSSA, which was within a range of 0–58.8% [12–16, 18–30] (Table 1). The highest prevalence of iMLSB phenotype among MRSA strains was reported in Egypt, 77.8% [29], followed by Nigeria, 75.0% [16]; Libya, 66.2% [12]; and Tanzania (61.5% [13]; 60.0% [18]). The lowest prevalence of the iMLSB phenotypes in MRSA strains was demonstrated in Côte d'Ivoire, 3.9% [24] (Figure 4). A zero prevalence of the iMLSB phenotype among MSSA strains was observed in 2007 and 2017 in Libya [12] and Côte d'Ivoire [24], respectively (Table 1). Additionally, cMLSB phenotype was

TABLE 1: Characteristics of studies reporting inducible clindamycin resistance in *S. aureus* isolates.

References	Study period	Country	Population	Specimen source	<i>S. aureus</i>	Detection method	iMLSB (%)	iMLSB in MRSA (%)	iMLSB in MSSA (%)	Resistance genes (%)
[12]	2007	Libya	Burn patients	Swabs from wounds, urine, blood, and others	120	<i>D</i> -test	35.8	43/65 (66.2)	0	—
[13]	2008	Tanzania	Surgical ward patients	Pus, wound swabs, and aspirates	160	<i>D</i> -test	28.8	16/26 (61.5)	30/134 (22.0)	—
[14]	2009 to 2010	Sudan	Healthcare workers and adult community children	Nasal swabs	114	<i>D</i> -test	25.4	10/23 (43.5)	19/91 (20.9)	—
[15]	2010	Tanzania	under the age of five	Nasal swabs	114	<i>D</i> -test	16.7	4/12 (33.3)	15/102 (14.7)	—
[16]	2012 to 2013	Nigeria	Inpatient or outpatient	Vaginal, cervical, wound, ear, and eye swabs, urine, blood, semen, and others	205	<i>D</i> -test	11.2	3/4 (75.0)	20/34 (58.8)	—
[17]	2012 to 2013	Uganda	Inpatient or outpatient	Blood, CSF, swabs of ear, vaginal, nasal, pus, throat, urethral, urine, and wound	300	<i>D</i> -test and PCR	33.3	NA	NA	ermB (7.7), ermC (32.7), and msrA (14.3) genes
[18]	2014 to 2015	Tanzania	Surgery patients and HCWs	Nasal and wound swabs	189	<i>D</i> -test	19.6	6/10 (60.0)	31/179 (17.3)	—
[19]	2015	Tanzania	Inpatients	Nasal swabs	89	<i>D</i> -test	21.3	7/22 (31.8)	12/67 (17.9)	—
[20]	2015 to 2016	Nigeria	Poultry workers	Swabs from palm	186	<i>D</i> -test	17.7	13/31 (41.9)	20/155 (12.9)	—
[21]	2016	Egypt	Children	Pus, wound and eye swabs, blood, urine, catheter, respiratory sample, ear discharge, and others	230	<i>D</i> -test and PCR	12.2	15/66 (22.7)	13/165 (7.9)	ermA (67.9), ermB (3.6), ermC (12.3), and both ermA and ermC (3.6) genes
[22]	2016 to 2017	Egypt	Children	Blood, wound swab, and bronchoalveolar lavage	107	<i>D</i> -test and PCR	44.0	27/65 (41.5)	20/42 (47.6)	ermA (29.0), ermC (18.7, ermB (4.6), both ermA and ermC (1.0), and ermA, ermB, and ermC (3.7)
[23]	2016 to 2018	Nigeria	Inpatients or outpatients	Wound and abscess, blood, urine, ear, nasal, vaginal, and urethral swabs	265	<i>D</i> -test	12.1	29/164 (17.7)	3/100 (3.0)	—
[24]	2017	Côte d'Ivoire	Inpatients or outpatients	Pus, blood, pleural fluid, sputum, wound, and urine	35	<i>D</i> -test	2.9	1/28 (3.6)	0	—
[25]	2017	Egypt	Inpatients or outpatients	Endotracheal aspirates, sputum, blood, urine, and wound swabs	210	<i>D</i> -test and PCR	10.0	18/195 (9.2)	3/15 (20.0)	ermB (20.0), erm C (70.0), msrA (70.0), mphC (40.0), and lnuA (20.0) genes
[26]	2017	Ethiopia	Inpatients or outpatients	Wound swabs	79	<i>D</i> -test	24.1	16/65 (24.6)	3/14 (21.4)	—

TABLE 1: Continued.

References	Study period	Country	Population	Specimen source	<i>S. aureus</i>	Detection method	iMLSB (%)	iMLSB in MRSA (%)	iMLSB in MSSA (%)	Resistance genes (%)
[27]	2017 to 2018	Egypt	Inpatients or outpatients	Urine, pus, wound, wound swab, blood, and aspirates	100	<i>D</i> -test	10.0	9/70 (12.8)	1/30 (3.3)	—
[28]	2017 to 2018	Sudan	Inpatients	Postoperative wound swabs	94	<i>D</i> -test	15.9	7/42 (16.7)	8/52 (15.4)	—
[29]	2017 to 2018	Egypt	Cancer patients with febrile neutropenia	Pus, throat swabs, blood, urine, and sputum	179	<i>D</i> -test and PCR	25.1	35/45 (77.8)	10/45 (22.2)	ermE (33.3) ermC (15.6), and both ermC and ermE (51.0) genes
[30]	2018 to 2019	Egypt	Inpatients or outpatients	Pus, blood, tracheal aspirates, urine, ascetic and synovial fluid	176	<i>D</i> -test and PCR	13.6	20/108 (18.5)	4/68 (5.9)	ermA (16.0), ermB (45.5), and ermC (50.0) genes
[31]	2019	Ethiopia	Cancer patients	Nasal swabs	59	<i>D</i> -test	17.0%	NA	NA	—
[32]	2020	Ethiopia	Prisoners	Nasal swabs	27	<i>D</i> -test	7.4%	NA	NA	—
[33]	2021	Ethiopia	Adults with CAP	Sputum	26	<i>D</i> -test	7.7%	NA	NA	—

iMLSB, inducible MLSB; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *Staphylococcus aureus*, PCR, polymerase chain reaction; CAP, community-acquired pneumonia; HCWs, healthcare workers; CSF, cerebral spinal fluid; NA, not available.

reported in MRSA and MSSA strains, ranging between 0–75.0% and 0–60.0%, respectively [12, 13, 15, 19–30] (S1).

4.2. Resistance Genes Related to MLSB Resistance. Despite the lack of complete information on the resistance genes, investigations have shown that many *S. aureus* isolates coproduced resistance genes such as erm (A, B, C, E) genes, msrA genes, mphC genes, and lnuA genes. Among the recovered erm genes in Egypt, the ermC gene was a highly detected resistance gene, at 70.0% [23], followed by the ermA gene, with a 67.9% detection rate [21]. The msrA gene was also detected among *S. aureus* isolates, with a 70.0% high detection rate in Egypt [23]. A study in Uganda also revealed ermC genes (32.7%) [17]. Additionally, the mphC genes (40.0%), and lnuA genes (20.0%) were also detected from a study in Egypt [25] (Table 1).

5. Discussion

The phenotypic analysis of the inducible resistance in *S. aureus* to clindamycin was demonstrated through the *D*-test across African countries. In this review study, the prevalence of inducible clindamycin resistance among the *S. aureus* isolates was found to be 19.8%, ranging from 2.9 to 44.0% [12–33]. Various studies have reported a comparable proportion of inducible clindamycin resistance among *S. aureus* isolates obtained from human sources such as studies in Odisha state, eastern India, 22.0% [7]; Nepal, 23.4% [34]; Malaysia, 22.1% [35]; and Israel, 20.0% to 25.0% [36]. This finding is significantly higher than the findings of

the iMLSB phenotype from the systematic review and meta-analysis in Iran with 10.4% overall prevalence [37]. In Indian studies, inducible clindamycin resistance rate was 5.2% in Kashmir valley [38], 7% in Assam [39], 15.2% in Chennai [40], 13.71% in the sub-Himalayan region [41], and 14.8% in central India [42]. In Nepal, lower inducible clindamycin resistance rate was indicated across different areas with a prevalence of 14.9% [43], 11.48% [8], 15.2% [44], and 12.1% [45]. While studies have also reported a high proportion of inducible clindamycin resistance as the prevalence in West Bengal, India, 41.3% [46]; Nepal (39.7% [47]; 34.8% [48]); Jordan, 76.7% [49]; and Tokyo, Japan, 91.0% [50]. The different iMLSB phenotypes observed in various studies are because of the variation in the study population, geographic region, the source of the specimen, methicillin susceptibility, usage of MLSB antibiotics in the community and hospital settings, and drug-resistant clones.

The emergence of inducible clindamycin resistance was comparatively higher among the clinical MRSA isolates as up to 77.8% recovered from cancer patients with febrile neutropenia [29]. In this study, the overall prevalence of inducible clindamycin resistance in MRSA strains was 26.8%. Comparable findings were reported in Nepal, 24.5% [44], and India (28.0% [41]; 25.0% [42]). Studies in Nepal (34.3% [47]; 76.4% [34]); India, 37.5% [51]; Malaysia, 46.7% [35]; and Jordan, 76.7% [49] demonstrated higher prevalence. However, this finding is higher than a study conducted in India (7.5% [39]; 18.7% [52]). The cMLSB phenotype prevalence in MRSA strain (28.9%) was in agreement with the study conducted in India, 29.26% [41], higher than studies conducted in Nepal (5.7% [47]; 11.2% [44]), India




FIGURE 2: Map of Africa showing number of articles from eight countries (Libya, Egypt, Tanzania, Ethiopia, Nigeria, Sudan, Uganda, and Côte d'Ivoire) which reported inducible clindamycin-resistant *S. aureus* (drawn from <https://mapchart.net/africa.html>).




FIGURE 3: The trend of inducible clindamycin-resistant *S. aureus* in Africa from 2007 to 2021.




FIGURE 4: The prevalence of iMLS B phenotype in MRSA strains in African countries (ordered using study period: Libya (2007), Tanzania (2008 to 2015), Sudan (2009 to 2018), Nigeria (2012 to 2018), Egypt (2016 to 2019), Côte d'Ivoire (2017), and Ethiopia (2017)). Abbreviations: iMLS B, inducible macrolide-lincosamide-streptogramin B; MRSA, methicillin-resistant *Staphylococcus aureus*.

(16.6% [51]; 16.9% [39]), and Malaysia, 11.1% [35], but lower than a study from India, 64.8% [42]. This shows that clindamycin treatment proved effective against MSSA infections, but it can lead to treatment failure in MRSA infections, and iMLS B phenotypes can be mutated into cMLS B phenotype.

The most common mechanism for MLS B resistance in *S. aureus* is the target site modification of 23S ribosomal RNA mediated by *erm* genes and strains exhibiting the iMLS B phenotype having a high frequency of spontaneous constitutive resistance mutations. Regarding the genotypic confirmation of MLS B resistance genes, our findings demonstrated that *erm* (A, B, C, E) genes and *msrA* genes were commonly detected genes. This finding is supported by other studies [34, 49, 53–58]. This indicates that the high spread and transmission of these genes significantly contribute to the increasing acquiring clindamycin resistance in *S. aureus* strains. As a limitation, the inclusion of studies with lower sample size results in a bias in the finding. Most studies studied only the prevalence of inducible clindamycin resistance; only a few studies reported resistance genes.

6. Conclusion

The current review study demonstrated a high prevalence of inducible clindamycin resistance *S. aureus* isolates with varying proportions throughout the country. A relatively higher number of iMLS B phenotypes was observed in MRSA than in MSSA isolates and a high figure was reported in Egypt, 77.8%, and Nigeria, 75.0%. Additionally, these strains are closely related to resistance genes such as the *ermA*, *ermC*, and *msrA* genes. Hence, there is an urgent need for ongoing studies to further assess iMLS B-positive *S. aureus* strains especially MRSA and in the revision of clindamycin prescription. Genotypic detection of resistance genes is mandatory to minimize treatment failure.

Abbreviations

CLSI: Clinical and Laboratory Standards Institute
 MLS B: Macrolide-lincosamide-streptogramin B
 cMLS B: Constitutive MLS B
 iMLS B: Inducible MLS B
 MRSA: Methicillin-resistant *Staphylococcus aureus*
 MSSA: Methicillin-sensitive *Staphylococcus aureus*
 PCR: Polymerase chain reaction.

Data Availability

All extracted data are freely available in the article and Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors' Contributions

MA conceived the review idea and content of the manuscript. MA also involved in data extraction, collection, and analysis and wrote the manuscript and was responsible for the final approval and submission of the manuscript.

Supplementary Materials

S1 Result. The table shows the prevalence of cMLS B phenotype in MRSA and MSSA strains in African countries. (*Supplementary Materials*)

References

- [1] K. M. Craft, J. M. Nguyen, L. J. Berg, and S. D. Townsend, "Methicillin-resistant *Staphylococcus aureus* (MRSA): antibiotic-resistance and the biofilm phenotype," *MedChemComm*, vol. 10, no. 8, pp. 1231–1241, 2019.
- [2] A. Tigabu and A. Getaneh, "*Staphylococcus aureus*, ESKAPE bacteria challenging current health care and community settings: a literature review," *Clinical Laboratory*, vol. 67, no. 7, 2021.
- [3] F. K. Wangai, M. M. Masika, M. C. Maritim, and R. A. Seaton, "Methicillin-resistant *Staphylococcus aureus* (MRSA) in East Africa: red alert or red herring?" *BMC Infectious Diseases*, vol. 19, no. 1, pp. 1–10, 2019.
- [4] D. J. Diekema, M. A. Pfaller, D. Shortridge, M. Zervos, and R. N. Jones, "Twenty-year trends in antimicrobial susceptibilities among *Staphylococcus aureus* from the SENTRY antimicrobial surveillance program," *Open Forum Infectious Diseases*, Oxford University Press, Oxford, UK, 2019.
- [5] C. J. Iwu-Jaja, A. Jaja, I. F. Jaja et al., "Preventing and managing antimicrobial resistance in the African region: a scoping review protocol," *PLoS One*, vol. 16, no. 7, Article ID e0254737, 2021.
- [6] A. M. Mtsher and Z. S. Aziz, "Estimation of erythromycin and inducible clindamycin resistance in *Staphylococcus aureus* isolated from clinical cases," *Research Journal of Pharmacy and Technology*, vol. 13, no. 6, pp. 2920–2924, 2020.
- [7] S. Majhi, M. Dash, D. Mohapatra, A. Mohapatra, and N. Chayani, "Detection of inducible and constitutive

- clindamycin resistance among *Staphylococcus aureus* isolates in a tertiary care hospital, Eastern India,” *Avicenna Journal of Medicine*, vol. 6, no. 3, pp. 75–80, 2016.
- [8] R. P. Adhikari, S. Shrestha, A. Barakoti, and R. Amatya, “Inducible clindamycin and methicillin resistant *Staphylococcus aureus* in a tertiary care hospital, Kathmandu, Nepal,” *BMC Infectious Diseases*, vol. 17, no. 1, pp. 483–485, 2017.
- [9] M. J. A. Miklasińska-Majdanik, “Mechanisms of resistance to macrolide antibiotics among *Staphylococcus aureus*,” *Antibiotics (Basel, Switzerland)*, vol. 10, no. 11, p. 1406, 2021.
- [10] G. Mahalakshmi, P. Neelusree, and M. Kalyani, “Phenotypic characterization and molecular detection of inducible and constitutive clindamycin resistance among *Staphylococcus aureus* isolates in a tertiary care hospital,” *Research Journal of Pharmacy and Technology*, vol. 14, no. 7, pp. 3799–3804, 2021.
- [11] P. Wayne, “Clinical and laboratory standards institute. performance standards for antimicrobial susceptibility testing,” *Inform Supply*, vol. 31, no. 1, pp. 100–121, 2021.
- [12] A. Zorgani, O. Shamerf, K. Tawil, E. El-Turki, and K. Ghenghesh, “Inducible clindamycin resistance among staphylococci isolated from burn patients,” *Libyan Journal of Medicine*, vol. 4, no. 3, pp. 104–106, 2009.
- [13] S. Mshana, E. E. Kamugisha, M. M. Mirambo et al., “Prevalence of clindamycin inducible resistance among methicillin-resistant *Staphylococcus aureus* at Bugando medical centre, Mwanza, Tanzania,” *Tanzania Journal of Health Research*, vol. 11, no. 2, pp. 59–64, 2009.
- [14] A. Mahmoud, H. Albadawy, S. Bolis, N. Bilal, A. Ahmed, and M. Ibrahim, “Inducible clindamycin resistance and nasal carriage rates of *Staphylococcus aureus* among healthcare workers and community members,” *African Health Sciences*, vol. 15, no. 3, pp. 861–867, 2015.
- [15] S. J. Moyo, S. Aboud, B. Blomberg et al., “High nasal carriage of methicillin-resistant *Staphylococcus aureus* among healthy Tanzanian under-5 children,” *Microbial Drug Resistance*, vol. 20, no. 1, pp. 82–88, 2014.
- [16] E. Godwin Nwukah and S. D. Abbey, “Inducible-Clindamycin Resistance in *Staphylococcus aureus* isolates in rivers state, Nigeria,” *American Journal of Clinical and Experimental Medicine*, vol. 4, no. 3, pp. 50–55, 2016.
- [17] B. Mwambi, J. Iramiot, F. Bwanga, M. Nakaye, H. Itabangi, and J. Bazira, “Clindamycin resistance among *Staphylococcus aureus* isolated at Mbarara regional referral hospital, in South Western Uganda,” *British Microbiology Research Journal*, vol. 4, no. 12, pp. 1335–1344, 2014.
- [18] N. Moremi, H. Claus, U. Vogel, and S. E. Mshana, “The role of patients and healthcare workers *Staphylococcus aureus* nasal colonization in occurrence of surgical site infection among patients admitted in two centers in Tanzania,” *Antimicrobial Resistance and Infection Control*, vol. 8, no. 1, pp. 102–107, 2019.
- [19] S. J. Moyo, L. Nkinda, M. Majigo et al., “Prevalence of methicillin-resistant *Staphylococcus aureus* carriage on admission among patients attending regional hospitals in Dares Salaam, Tanzania,” *BMC Research Notes*, vol. 10, no. 1, pp. 1–7, 2017.
- [20] O. Okojokwu, E. Akpakpan, H. Azi, B. Abubakar, and J. J. I. M. B. Anejo-Okopi, “Inducible clindamycin resistance in *Staphylococcus aureus* isolated from palms of poultry workers in Jos, Plateau State, Nigeria,” *Journal of Infection and Molecular Biology*, vol. 6, no. 1, pp. 11–15, 2018.
- [21] N. M. Al-Kasaby and N. T. A. El-Khier, “Phenotypic and genotypic detection of macrolide-lincosamide-streptogramin B resistance among clinical isolates of *Staphylococcus aureus* from Mansoura University children hospital, Egypt,” *African Journal of Microbiology Research*, vol. 11, no. 12, pp. 488–494, 2017.
- [22] A. Abouelnour, M. Zaki, R. Hassan, and S. Elkannishy, “Phenotypic and genotypic identification of *Staphylococcus aureus* resistant to clindamycin in Mansoura university children hospital, Egypt,” *African Journal of Clinical and Experimental Microbiology*, vol. 21, no. 1, pp. 30–35, 2020.
- [23] A. C. Ifediora, R. N. Nwabueze, E. S. Amadi, and C. I. Chikwendu, “Methicillin and inducible clindamycin-resistant *Staphylococcus aureus* isolates from clinical samples in Abia State,” *Microbiology Research Journal International*, vol. 29, no. 4, pp. 1–9, 2019, <https://www.journalmrji.com/index.php/MRJI/article/view/30167#citeTab>.
- [24] S. M. Kouam e-Sina, D. C. N’Golo, F. Konan et al., “Antibiotics resistance patterns of panton-valentine leukocidin-positive methicillin-resistant staphylococci isolated from clinical samples in Abidjan, Cte d’Ivoire,” *African Journal of Microbiology Research*, vol. 12, no. 41, pp. 938–946, 2018.
- [25] O. El Badawy, M. Abdel-Rahim, A. Zahran, and N. Elsherbiny, “Phenotypic and genotypic characterization of macrolide, lincosamide and streptogramin resistance among nosocomial staphylococci isolated from intensive care units,” *Egyptian Journal of Medical Microbiology*, vol. 28, no. 1, pp. 23–29, 2018.
- [26] M. Mama, A. Aklilu, K. Misgna, M. Tadesse, and E. Alemayehu, “Methicillin- and inducible clindamycin-resistant *Staphylococcus aureus* among patients with wound infection attending Arba minch hospital, South Ethiopia,” *International Journal of Microbiology*, vol. 2019, Article ID 2965490, 9 pages, 2019.
- [27] Y. E. Abdelmawgoud, A. El-Latif, N. K. Fawzy, and S. M. Elnagdy, “Prevalence of inducible clindamycin resistance and nanotechnological control of *Staphylococcus aureus* clinical isolates,” *Egyptian Journal of Botany*, vol. 62, no. 1, pp. 73–84, 2022.
- [28] A. E. Abdalla, A. B. Kabashi, M. E. Elobaid et al., “Methicillin and inducible clindamycin-resistant *Staphylococcus aureus* isolated from postoperative wound samples,” *Journal of Pure and Applied Microbiology*, vol. 13, no. 3, pp. 1605–1609, 2019.
- [29] R. A. A. El-Din, H. El-Bassat, M. El-Bedewy, and M. A. A. El-Din, “Phenotypic and molecular characterization of inducible clindamycin resistance among staphylococcal strains isolated from cancer patients with febrile neutropenia,” *African Journal of Microbiology Research*, vol. 12, no. 41, pp. 947–952, 2018.
- [30] R. M. Kishk, M. M. Anani, N. A. Nemr, N. M. Soliman, and M. M. Fouad, “Inducible clindamycin resistance in clinical isolates of *Staphylococcus aureus* in Suez canal university hospital, Ismailia, Egypt,” *The Journal of Infection in Developing Countries*, vol. 14, no. 11, pp. 1281–1287, 2020.
- [31] A. Tigabu and G. Belay, “Inducible clindamycin and methicillin resistant *Staphylococcus aureus* among cancer patients at university of gondar compressive specialized hospital, Northwest Ethiopia: carriage rate and antibiotic resistance patterns,” *Clinical Laboratory*, vol. 66, no. 11, 2020.
- [32] G. Mamo, G. Ferede, and T. B. Eshete, “Nasal carriage rate, antimicrobial susceptibility patterns and associated risk factors of methicillin-resistant *Staphylococcus aureus* among prisoners in Dessie town, Northeast Ethiopia,” *Research Square*, vol. 1, pp. 1–22, 2020.
- [33] M. Assefa, A. Tigabu, T. Belachew, and B. Tessema, “Bacterial profile, antimicrobial susceptibility patterns, and associated factors of community-acquired pneumonia among adult

- patients in Gondar, Northwest Ethiopia: a cross-sectional study," *PLoS One*, vol. 17, no. 2, Article ID e0262956, 2022.
- [34] R. Timsina, U. Shrestha, A. Singh, and B. Timalisina, "Inducible clindamycin resistance and erm genes in *Staphylococcus aureus* in school children in Kathmandu, Nepal," *Future Science OA*, vol. 7, no. 1, Article ID FSO361, 2020.
- [35] A. M. Che Hamzah, C. C. Yeo, S. M. Puah et al., "Tigecycline and inducible clindamycin resistance in clinical isolates of methicillin-resistant *Staphylococcus aureus* from Terengganu, Malaysia," *Journal of Medical Microbiology*, vol. 68, no. 9, pp. 1299–1305, 2019.
- [36] M. Stein, J. Komerska, M. Prizade, B. Sheinberg, D. Tasher, and E. Somekh, "Clindamycin resistance among *Staphylococcus aureus* strains in Israel: implications for empirical treatment of skin and soft tissue infections," *International Journal of Infectious Diseases*, vol. 46, pp. 18–21, 2016.
- [37] M. Memariani, H. Memariani, and H. Moravvej, "Inducible clindamycin resistance among clinical *Staphylococcus aureus* strains in Iran: a contemporaneous systematic review and meta-analysis," *Gene Reports*, vol. 23, Article ID 101104, 2021.
- [38] S. Farooq and M. Saleem, "Prevalence of constitutive and inducible clindamycin resistance among clinical isolates of Staph aureus in Kashmir valley: a hospital based study," *Journal of Evolution of Medical and Dental Sciences*, vol. 5, no. 17, pp. 828–831, 2016.
- [39] C. Phukan, G. Ahmed, and P. Sarma, "Inducible clindamycin resistance among *Staphylococcus aureus* isolates in a tertiary care hospital of Assam," *Indian Journal of Medical Microbiology*, vol. 33, no. 3, pp. 456–458, 2015.
- [40] E. Kavitha, R. Srikumar, and G. Muthu, "Inducible clindamycin resistance among clinical isolates from a tertiary care hospital," *Research Journal of Pharmacy and Technology*, vol. 11, no. 11, pp. 5008–5012, 2018.
- [41] K. K. Mokta, S. Verma, D. Chauhan et al., "Inducible clindamycin resistance among clinical isolates of *Staphylococcus aureus* from sub Himalayan region of India," *Journal of Clinical and Diagnostic Research: Journal of Clinical and Diagnostic Research*, vol. 9, no. 8, pp. DC20–DC23, 2015.
- [42] T. Singh, A. B. Deshmukh, V. Chitnis, and T. Bajpai, "Inducible clindamycin resistance among the clinical isolates of *Staphylococcus aureus* in a tertiary care hospital," *International Journal of Health & Allied Sciences*, vol. 5, no. 2, pp. 111–114, 2016.
- [43] B. Ujwol, R. K. Raj, N. Biswas et al., "Status of inducible clindamycin resistance among macrolide resistant *Staphylococcus aureus*," *African Journal of Microbiology Research*, vol. 10, no. 9, pp. 280–284, 2016.
- [44] R. Baral and B. Khanal, "Inducible clindamycin resistance in *Staphylococcus aureus* strains isolated from clinical samples," *International Journal of Biomedical Research*, vol. 8, no. 2, pp. 81–84, 2017.
- [45] P. Sah, R. Khanal, P. Lamichhane, S. Upadhaya, A. Lamsal, and V. K. Pahwa, "Inducible and constitutive clindamycin resistance in *Staphylococcus aureus*: an experience from Western Nepal," *International Journal of Biomedical Research*, vol. 6, no. 5, pp. 316–319, 2015.
- [46] S. Ghosh and M. Banerjee, "Methicillin resistance & inducible clindamycin resistance in *Staphylococcus aureus*," *Indian Journal of Medical Research*, vol. 143, no. 3, pp. 362–4, 2016.
- [47] R. S. Regmi, S. Khadka, S. Sapkota et al., "Phenotypic detection of inducible clindamycin resistance among clinical isolates of *Staphylococcus aureus* in Bharatpur hospital," *Journal of College of Medical Sciences-Nepal*, vol. 16, no. 3, 2020.
- [48] S. Manandhar, A. Singh, A. Varma, S. Pandey, and N. Shrivastava, "Biofilm producing clinical *Staphylococcus aureus* isolates augmented prevalence of antibiotic resistant cases in tertiary care hospitals of Nepal," *Frontiers in Microbiology*, vol. 9, p. 2749, 2018.
- [49] D. Jarajreh, A. Aqel, H. Alzoubi, and W. Al-Zereini, "Prevalence of inducible clindamycin resistance in methicillin-resistant *Staphylococcus aureus*: the first study in Jordan," *Journal of Infection in Developing Countries*, vol. 11, no. 04, pp. 350–354, 2017.
- [50] K. Shoji, M. Shinjoh, Y. Horikoshi et al., "High rate of inducible clindamycin resistance in *Staphylococcus aureus* isolates—a multicenter study in Tokyo, Japan," *Journal of Infection and Chemotherapy*, vol. 21, no. 2, pp. 81–83, 2015.
- [51] M. Lall and A. K. Sahni, "Prevalence of inducible clindamycin resistance in *Staphylococcus aureus* isolated from clinical samples," *Medical Journal Armed Forces India*, vol. 70, no. 1, pp. 43–47, 2014.
- [52] A. V. Kavitha, "Inducible clindamycin resistance among *Staphylococcus aureus* isolates from various clinical samples," *University Journal of Pre and Paraclinical Sciences*, vol. 6, no. 8, 2020.
- [53] M. Moosavian, S. Shoja, S. Rostami, M. Torabipour, and Z. Farshadzadeh, "Inducible clindamycin resistance in clinical isolates of *Staphylococcus aureus* due to erm genes, Iran," *Iranian Journal of Microbiology*, vol. 6, no. 6, p. 421, 2014.
- [54] R. Timsina, B. Timalisina, and A. Singh, "Screening of erm gene of inducible clindamycin resistant *Staphylococcus aureus*," *Journal of Institute of Science and Technology*, vol. 24, no. 2, pp. 39–43, 2019.
- [55] H. Wang, H. Zhuang, S. Ji et al., "Distribution of erm genes among MRSA isolates with resistance to clindamycin in a Chinese teaching hospital," *Infection, Genetics and Evolution*, vol. 96, Article ID 105127, 2021.
- [56] M. J. Mazloumi, R. Akbari, S. J. M. Yousefi, and B. Letters, "Detection of inducible clindamycin resistance genes (ermA, ermB, and ermC) in *Staphylococcus aureus* and *Staphylococcus Epidermidis*," *Microbiology and Biotechnology Letters*, vol. 49, no. 3, pp. 449–457, 2021.
- [57] A. Hashemi, S. Jaber, A. Shariati et al., "Identification of inducible clindamycin resistance in *Staphylococcus aureus* strains isolated from hospitalized patients in hospitals of Tehran city (Iran)," *Qom University of Medical Sciences Journal*, vol. 11, no. 12, pp. 52–60, 2018.
- [58] M. Khodabandeh, M. Mohammadi, M. R. Abdolsalehi et al., "Analysis of resistance to macrolide-lincosamide-streptogramin B among mecA-positive *Staphylococcus aureus* isolates," *Osong Public Health and Research Perspectives*, vol. 10, no. 1, pp. 25–31, 2019.